Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29548682 | 0.98 | TAAR1 (0.48) | TAAR1HTR2ACYP1A2CYP2A6TACR1 | |
| Hydrochloric Acid SCHEMBL6913336 | 0.98 | TAAR1 (0.48) | TAAR1HTR2ACYP1A2CYP2A6TACR1 | |
| SCHEMBL17277452 | 0.86 | MAOA (0.41) | TAAR1HTR2ACYP1A2CYP2A6TACR1 | |
| SCHEMBL537203 | 0.84 | TAAR1 (0.60) | TAAR1HTR2ACYP1A2CYP2A6HTR2C | |
| SCHEMBL5705697 | 0.84 | TAAR1 (0.60) | TAAR1HTR2ACYP1A2CYP2A6HTR2C | |
| SCHEMBL3849051 | 0.84 | TAAR1 (0.60) | TAAR1HTR2ACYP1A2CYP2A6HTR2C | |
| SCHEMBL1363875 | 0.82 | TACR1 (0.44) | TAAR1HTR2ACYP1A2CYP2A6TACR1 | |
| Hydrochloric Acid SCHEMBL5151143 | 0.81 | TAAR1 (0.58) | TAAR1HTR2ACYP1A2CYP2A6HTR2C | |
| Hydrochloric Acid SCHEMBL4409416 | 0.81 | TAAR1 (0.58) | TAAR1HTR2ACYP1A2CYP2A6HTR2C | |
| SCHEMBL16955117 | 0.80 | TACR1 (0.39) | TAAR1TACR1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| WO-2022068848-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2022-04-07 | — | — | WO | disclosed |
| US-RE46886-E1 | Alkoxy pyrazoles as soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-8906904-B2 | Alkoxy pyrazoles as soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20140073629-A1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8119800-B2 | Processes for preparing HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-02-21 | — | — | US | disclosed |
| WO-2009085797-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1112998-B1 | AMINE DERIVATIVES | POLA CHEM IND INC (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-6586633-B1 | Antifungal agents | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1112998-A1 | AMINE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | TAAR1 4113/4885HTR2A 1612/4885CYP1A2 3877/4885 |
| US-20140073629-A1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | TAAR1 1012/4885HTR2A 1363/4885CYP1A2 299/4885 |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | POLB, POLR2E, POLR2H | TAAR1 4580/4885HTR2A 4776/4885CYP1A2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.